On the Mayo Clinic Radio program, Dr. Derek Lomas, a Mayo Clinic urologist, discusses prostate cancer, including a new biopsy method.
This interview originally aired Feb. 22, 2020. Prostate cancer is the second most common cancer — second to skin cancer — among men in the U.S. One in 9 men will be diagnosed with prostate cancer in his lifetime, according to the American Cancer Society. Screening is important because early detection greatly improves the chances of survival. While some types of prostate cancer grow slowly, and may need minimal or even no treatment, other types are aggressive and can spread quickly. If prostate cancer is suspected, a biopsy can confirm the diagnosis.
Learn more about prostate cancer: https://www.mayoclinic.org/diseases-c…
Although coronavirus disease 2019 (COVID-19) dominates the news in early 2020, it affects few people in the US. In contrast, at the same time the US is experiencing a severe influenza epidemic, which has caused an estimated 250 000 hospitalizations and 14 000 deaths.

The hope, Lee says, is that ultrasound will kill cancer cells in a specific way that will also engage the immune system and arouse it to attack any cancer cells remaining after the treatment.
Ultrasound waves—sound waves with frequencies higher than humans can hear—have been used as a cancer treatment before, albeit in a broad-brush approach: high-intensity bursts of ultrasound can heat up tissue, killing cancer and normal cells in a target area. Now, scientists and engineers are exploring the use of low-intensity pulsed ultrasound (LIPUS) in an effort to create a more selective treatment.
Featuring articles on lung-cancer screening in the NELSON trial, ribociclib and fulvestrant in metastatic breast cancer, vitamin D in pregnancy and asthma, treatment thresholds for neonatal hypoglycemia, and CAR-NK cells in anti-CD19 lymphoid tumors; a review article on placebo and nocebo effects; a Clinical Problem-Solving describing a rapid change in pressure; and Perspective articles on altruism in Extremis, on abuses of FDA regulatory procedures, and on joining forces against delirium.